EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Long‐term oncological outcomes of bladder cancer: a population‐based study with a 25‐year follow‐up

Linda Dey iD, Juhana Rautiola iD, Olof Akre, Lars Egevad iD, Abolfazl Hosseini, Reza Mehrazin, Jaakko Patrakka, Daniel Ranti iD, Lotta Renström-Koskela, John Sfakianos, Tomas Thiel iD, Per Henrik Vincent und 3 weitere

BJU International · 2026-01 · 137 (1) · 95-102

DOI: 10.1111/bju.16883 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 07.08.2025. Verfasst von Linda Dey und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Region Stockholm research grant, Signe and Olof Wallenius Stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe the oncological outcomes for patients with newly diagnosed bladder cancer, as long‐term oncological outcomes and natural history of different initial subtypes of diagnoses of bladder cancer are understudied. Patients and Methods This was a prospective, multicentre population‐based cohort study, where newly diagnosed patients with bladder cancer from 1995 to 1996 in Stockholm County, Sweden were followed. The primary outcome was cancer‐specific mortality (CSM), separately analysed for low‐grade non‐muscle‐invasive bladder cancer (NMIBC Low), high‐grade non‐muscle‐invasive bladder cancer (NMIBC High), and muscle‐invasive bladder cancer (MIBC). We used cumulative incidence with competing risk to assess survival outcomes.

Results

In total, 526 patients were included, 396 had NMIBC. Out of 102 patients with T1, 37% died of bladder cancer during the 25‐year follow‐up. The rate of CSM for NMBIC Low was 3%, NMIBC High 26%, and MIBC 71%, respectively. For the operated patients with MIBC, the 5‐year CSM was 39%. Of the 178 patients with NMIBC High, 22% progressed to MIBC, 10% had lymph node progression, and 17% progressed to metastatic disease during the follow‐up. The main limitation of the study is that it was established 30 years ago.

Conclusion

In this population‐based study, we found that patients with NMIBC High had a persistent risk of CSM up to 25 years from the initial diagnosis, more specifically in patients with T1 tumours. The study demonstrates the importance for optimal treatment for selective high‐risk T1 patients with long life expectancy, and high risk of progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedFollow-Up StudiesProspective StudiesSweden

Stichwörter der Autor:innen

bladder cancercancer‐specific mortalitylong‐term follow‐upprogressionurothelial cancer

Autor:innen und Institutionen

  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Linda Dey, Juhana Rautiola, Lars Egevad, Daniel Ranti, Tomas Thiel

Förderung

  • Region Stockholm research grant
  • Signe and Olof Wallenius Stiftelse

Zitieren

APA

Dey, L., Rautiola, J., Akre, O., Egevad, L., Hosseini, A., Mehrazin, R., Patrakka, J., Ranti, D., Renström-Koskela, L., Sfakianos, J., Thiel, T., Vincent, P. H., Yan, J., Steineck, G., & Wiklund, P. (2026). Long‐term oncological outcomes of bladder cancer: a population‐based study with a 25‐year follow‐up. BJU International, 137(1), 95-102. https://doi.org/10.1111/bju.16883

Vancouver

Dey L, Rautiola J, Akre O, Egevad L, Hosseini A, Mehrazin R, et al. Long‐term oncological outcomes of bladder cancer: a population‐based study with a 25‐year follow‐up. BJU International. 2026;137(1):95-102. doi:10.1111/bju.16883

BibTeX
@article{Dey2026,
  author = {Dey, Linda and Rautiola, Juhana and Akre, Olof and Egevad, Lars and Hosseini, Abolfazl and Mehrazin, Reza and Patrakka, Jaakko and Ranti, Daniel and Renström-Koskela, Lotta and Sfakianos, John and Thiel, Tomas and Vincent, Per Henrik and Yan, Jane and Steineck, Gunnar and Wiklund, Peter},
  title = {Long‐term oncological outcomes of bladder cancer: a population‐based study with a 25‐year follow‐up},
  journal = {BJU International},
  year = {2026},
  volume = {137},
  number = {1},
  pages = {95--102},
  doi = {10.1111/bju.16883}
}
Kostenlos starten →